Prescription ·Strong evidence ·Reviewed May 2026
Carvedilol is a unique third-generation beta-blocker that combines non-selective beta-blockade with alpha-1 receptor antagonism and antioxidant properties. The COPERNICUS trial demonstrated a 35% reduction in mortality in severe heart failure, establishing it as a cornerstone of HF therapy.
The bottom line
Evidence rating strong. Most-documented uses: reduces mortality in heart failure (copernicus, comet trials), provides vasodilation via alpha-1 blockade, improves insulin sensitivity relative to other beta-blockers. 10 sources indexed (2014–2024), with 6 interaction records on file.
Core mechanism
Non-selectively blocks beta-1 and beta-2 adrenergic receptors and additionally blocks alpha-1 receptors. Alpha-1 blockade provides vasodilation and reduces peripheral resistance without reflex tachycardia (due to concurrent beta-blockade). Also has antioxidant and anti-proliferative properties that may confer additional cardioprotection.2
Should be taken with food to slow absorption and reduce risk of orthostatic hypotension
Nutrients this medication can lower over time, and what to replace.
Chronic beta-blocker therapy has been associated with lower tissue CoQ10 status and reduced mitochondrial electron transport support.
Carvedilol, as a non-selective beta-blocker, suppresses nocturnal melatonin synthesis more than beta-1 selective agents. Melatonin supplementation can restore sleep quality.
Recommendation: Melatonin 0.5-3mg at bedtime may help with carvedilol-induced insomnia.
Beta-blockers may reduce CoQ10 levels. CoQ10 supplementation is particularly relevant for carvedilol patients with heart failure, as CoQ10 supports mitochondrial function in failing myocardium.
Recommendation: Consider CoQ10 100-200mg/day for heart failure patients on carvedilol. The Q-SYMBIO trial showed CoQ10 reduced CV mortality in HF.
L-Carnitine supports fatty-acid oxidation in cardiomyocytes and modestly lowers diastolic blood pressure. In heart failure patients on carvedilol, L-carnitine has been used adjunctively to improve cardiac energetics and exercise tolerance.
Recommendation: L-Carnitine 1-2 g/day is generally compatible with carvedilol and may provide additional cardiac support. Discuss with your cardiologist before starting, especially if you have heart failure.
Taurine modestly lowers blood pressure and heart rate and has heart-rate physiology effects. Combined with carvedilol (which blocks alpha1, beta1, and beta2 receptors), the cumulative drop in BP and HR can be larger than with a more selective beta-blocker.
Recommendation: Taurine 1-3 g/day is generally safe with carvedilol but monitor resting heart rate and blood pressure when starting. Reduce or stop if HR drops below 50 bpm or you develop dizziness, especially on standing.
Acetyl-L-carnitine supports fatty-acid oxidation and mitochondrial function in cardiac muscle. Carvedilol partially inhibits mitochondrial Complex I, so ALCAR's bioenergetic support may help offset this effect, especially in heart failure or ischemic cardiomyopathy.
Recommendation: Acetyl-L-carnitine 500-1500 mg/day is generally compatible with carvedilol and may add cardiac benefit. Discuss with your cardiologist before starting, especially if you have heart failure.
Omega-3 fatty acids modestly reduce blood pressure and lower triglycerides, and have separate benefits in heart failure (reducing all-cause mortality in some trials). Combined with carvedilol, the regimen is broadly cardioprotective, with minimal interaction risk at typical doses.
Recommendation: Fish oil 1-3 g/day is appropriate alongside carvedilol for most cardiovascular patients. Monitor blood pressure when starting and tell your prescriber if you take high doses (>3 g/day).
Numbered references. Citations throughout the page link here.
Abouzid MR, Vyas A, Eldahtoury S et al.. Which should you choose for post operative atrial fibrillation, carvedilol or metoprolol? A systemic review and meta-analysis. Current problems in cardiology. 2024
Huang S, Zhao Q, Yang ZG et al.. Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol. Heart failure reviews. 2019
Kheiri B, Abdalla A, Osman M et al.. Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity. The American journal of cardiology. 2018
Li T, Ke W, Sun P et al.. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ open. 2016
Aguilar-Olivos N, Motola-Kuba M, Candia R et al.. Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis. Annals of hepatology. 2014
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack